Author:
Kalamarides Daniel J.,Singh Aditi,Wolfman Shannon L.,Dani John A.
Abstract
AbstractThe effectiveness of current treatments for opioid use disorder (OUD) varies by sex. Our understanding of the neurobiological mechanisms mediating negative states during withdrawal is lacking, particularly with regard to sex differences. Based on preclinical research in male subjects, opioid withdrawal is accompanied by increased gamma-aminobutyric acid (GABA) release probability at synapses onto dopamine neurons in the ventral tegmental area (VTA). It is unclear, however, if the physiological consequences of morphine that were originally elucidated in male rodents extend to females. The effects of morphine on the induction of future synaptic plasticity are also unknown. Here, we show that inhibitory synaptic long-term potentiation (LTPGABA) is occluded in the VTA in male mice after repeated morphine injections and 1 day of withdrawal, while morphine-treated female mice maintain the ability to evoke LTPGABA and have basal GABA activity similar to controls. Our observation of this physiological difference between male and female mice connects previous reports of sex differences in areas upstream and downstream of the GABA-dopamine synapse in the VTA during opioid withdrawal. The sex differences highlight the mechanistic distinctions between males and females that can be targeted when designing and implementing treatments for OUD.
Funder
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke
Chernowitz Medical Research Foundation
Publisher
Springer Science and Business Media LLC
Reference82 articles.
1. Substance Abuse and Mental Health Services Administration. National Survey of Substance Abuse Treatment Services (N-SSATS): 2020. Data on Substance Abuse Treatment Facilities. https://www.samhsa.gov/data/sites/default/files/reports/rpt35313/2020_NSSATS_FINAL.pdf (2021).
2. Lee, J. D. et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): A multicentre, open-label, randomised controlled trial. Lancet Lond. Engl. 391, 309–318 (2018).
3. Hser, Y.-I. et al. Long-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi-site trial. Addict. Abingd. Engl. 111, 695–705 (2016).
4. Sinha, R. New findings on biological factors predicting addiction relapse vulnerability. Curr. Psychiatry Rep. 13, 398–405 (2011).
5. George, O. & Koob, G. F. Individual differences in the neuropsychopathology of addiction. Dialogues Clin. Neurosci. 19, 217–229 (2017).
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献